(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 October 2021 (14.10.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/205032 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) *A61K 47/54* (2017.01)
A61P 11/00 (2006.01) *A61P 31/14* (2006.01)
A61K 9/00 (2006.01)

(21) International Application Number:
PCT/EP2021/059360

(22) International Filing Date:
09 April 2021 (09.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20169160.7 09 April 2020 (09.04.2020) EP

(71) Applicant: **TECHNISCHE UNIVERSITÄT MÜNCHEN** [DE/DE]; Arcisstr. 21, 80333 München (DE).

(72) Inventors: **ENGELHARDT, Stefan**; Institute of Pharmacology and Toxicology, Technische Universität München (TUM), Biedersteiner Strasse 29, 80802 München (DE). **RAMANUJAM, Deepak Prabhu**; Institute of Pharmacology and Toxicology, Technische Universität München (TUM), Biedersteiner Strasse 29, 80802 München (DE).

(74) Agent: **JÜRGEN MEIER, VOSSIUS & PARTNER**; Patentanwälte Rechtsanwälte mbB, Siebertstrasse 3, 81675 München (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2021/205032 A1

(54) Title: TARGETED DELIVERY OF AN INHIBITOR OF MIR-21 TO MACROPHAGES FOR THE TREATMENT OF PULMONARY FIBROSIS

(57) Abstract: The present invention relates to a composition for use in the treatment of pulmonary fibrosis of a subject, wherein the composition comprises an inhibitor of miR-21 and a moiety that delivers said inhibitor of miR-21 to a macrophage. Further, the composition may be administered by a pulmonary administration. In particular aspects, said subject to be treated suffers from pulmonary fibrosis and further has a lung disease or disorder, wherein the lung disease or disorder may be a corona virus disease. Furthermore, the invention relates to a composition, wherein the composition comprises an inhibitor of miR-21 and a moiety that delivers said inhibitor of miR-21 to a lung macrophage.